Peptide Schedule
Kisspeptin-1010 residuesYNWNSFGLRFEach bubble = one amino acid. Size = residue mass. Color = chemical class.Kisspeptin-10
Benefits
About Kisspeptin-10
Kisspeptin-10 is the active fragment of kisspeptin, the master regulator of the hypothalamic-pituitary-gonadal (HPG) axis. It binds to the KISS1R receptor on GnRH neurons, triggering a cascade that releases GnRH, which then stimulates LH and FSH from the pituitary. This makes it a potent, natural stimulator of reproductive hormones including testosterone and estrogen. It's under clinical investigation for infertility, hypogonadism, and as a diagnostic tool for pubertal disorders.
Who Should Consider Kisspeptin-10
- Men with functional hypogonadotropic hypogonadism seeking natural testosterone stimulation
- Women undergoing IVF at high risk of ovarian hyperstimulation syndrome (OHSS)
- Adults being evaluated for pubertal or hypothalamic reproductive disorders (diagnostic use)
- Couples with unexplained infertility where HPG axis dysfunction is suspected
- Researchers studying neuroendocrine control of reproduction
How Kisspeptin-10 Works
Kisspeptin-10 is the minimal bioactive fragment (amino acids 112-121) of the KISS1 gene product. It binds with high affinity to the KISS1R (GPR54) receptor, a G-protein coupled receptor expressed on gonadotropin-releasing hormone (GnRH) neurons in the arcuate and anteroventral periventricular nuclei of the hypothalamus. Receptor activation triggers Gq/11-mediated signaling, which increases intracellular calcium and activates protein kinase C, directly depolarizing GnRH neurons. This causes pulsatile GnRH secretion into the hypophyseal portal system at the median eminence, which lacks a complete blood-brain barrier. GnRH then acts on gonadotroph cells in the anterior pituitary, stimulating release of both luteinizing hormone (LH) and follicle-stimulating hormone (FSH). The LH pulse that follows a kisspeptin-10 bolus peaks within 30-40 minutes and returns to baseline within approximately 3 hours. In men, this drives Leydig cell testosterone production. In women, the response depends on menstrual cycle phase, with the strongest LH release during the preovulatory period. Kisspeptin neurons also integrate metabolic signals (leptin, insulin, ghrelin) and photoperiod cues, serving as a gatekeeping node that couples energy status and environmental conditions to reproductive output. Repeated or continuous kisspeptin-10 exposure can lead to GnRH neuron desensitization and reduced gonadotropin output — a property being explored for conditions like endometriosis and precocious puberty where suppression of the reproductive axis is desired.
What to Expect
After IV or SC injection, plasma kisspeptin levels peak within 10-15 minutes. A measurable rise in serum LH begins within 15-20 minutes. No subjective effects are typically noticed.
Peak LH response occurs at 30-40 minutes post-injection. FSH also rises but with a smaller magnitude. In men, testosterone begins to increase following the LH spike.
LH levels gradually return to baseline by approximately 3 hours. Testosterone elevation persists slightly longer in men. The acute hormonal cascade is complete.
With daily subcutaneous dosing, repeated LH pulses are observed. Some studies show sustained elevation of mean LH levels and increased LH pulse frequency over 1-2 weeks of administration.
Tachyphylaxis may develop with continuous exposure. Pulsatile or intermittent dosing protocols may better maintain responsiveness. Testosterone and gonadotropin changes should be monitored by bloodwork.
Dosing Protocol
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 100mcg | Daily |
| Moderate | 500mcg | Daily |
| Aggressive | 1mg | Daily |
Note: Stimulates GnRH → LH/FSH release. Short-acting — subcutaneous extends duration. Investigated for hypogonadism and fertility. May acutely boost testosterone. Research-stage peptide.
How to Inject Kisspeptin-10
Inject subcutaneously into abdominal fat or the anterior thigh. Kisspeptin-10 has a very short half-life, so consistent timing matters. For testosterone stimulation protocols, administer 1-2 times daily at the same times each day. Rotate injection sites. Store reconstituted peptide refrigerated and use within 2 weeks. Blood draws for LH and testosterone 30-60 minutes post-injection can confirm individual response.
Cycling Protocol
Due to potential tachyphylaxis with continuous dosing, pulsatile or intermittent protocols are preferred. Some researchers use twice-daily injections for 1-2 weeks followed by a washout. Monitor LH and testosterone to assess ongoing responsiveness.
Pharmacokinetics
Source: IV terminal half-life of ~4 minutes in humans; subcutaneous administration extends effective duration to ~30 minutes due to slower absorption from the injection depot (PMID 21632807)
Loading the interactive decay curve.
Side Effects
Generally well-tolerated in clinical studies. Headache, nausea, and hot flushes reported. Very short half-life requires subcutaneous dosing for sustained effect.
Contraindications
- Pregnancy — kisspeptin stimulates gonadotropin release which could disrupt early pregnancy hormone balance; not studied for safety in pregnant women
- Hormone-sensitive cancers (breast, prostate, ovarian) — acute gonadotropin stimulation may temporarily increase sex steroid levels
- Precocious puberty — exogenous kisspeptin could worsen premature activation of the HPG axis
- Children and adolescents — not studied for safety in pediatric populations outside diagnostic settings
- Known hypersensitivity to kisspeptin peptides or any excipients
- Severe hepatic or renal impairment — clearance kinetics have not been characterized in these populations
Drug Interactions
- GnRH agonists (leuprolide, goserelin) — concurrent use may cause unpredictable gonadotropin responses; kisspeptin acts upstream of GnRH
- GnRH antagonists (cetrorelix, ganirelix) — may blunt the LH response to kisspeptin by blocking pituitary GnRH receptors
- Testosterone replacement therapy — exogenous testosterone suppresses endogenous LH via negative feedback, potentially reducing kisspeptin effectiveness
- Oral contraceptives and estrogen/progesterone therapy — steroid feedback on the hypothalamus and pituitary may alter kisspeptin-induced gonadotropin release
- Clomiphene citrate — both act to increase gonadotropin output; combined effects have not been studied
- Opioid analgesics — endogenous opioids suppress kisspeptin neuron activity; chronic opioid use may reduce kisspeptin responsiveness
Storage & Stability
Molecular Profile
Related Peptides
References
- The kisspeptin-GnRH pathway in human reproductive health and disease (Hum Reprod Update 2014)PubMed 24615662
- Kisspeptin-10 is a potent stimulator of LH and increases pulse frequency in men (J Clin Endocrinol Metab 2011)PubMed 21632807
- The effects of kisspeptin-10 on reproductive hormone release show sexual dimorphism in humans (J Clin Endocrinol Metab 2011)PubMed 21976724
- Kisspeptin and the hypothalamic control of reproduction: lessons from the human (Endocrinology 2012)PubMed 23015291
- Efficacy of kisspeptin-54 to trigger oocyte maturation in women at high risk of OHSS during IVF therapy (J Clin Endocrinol Metab 2015)PubMed 26192876
- The KiNG of reproduction: kisspeptin/nNOS interactions shaping hypothalamic GnRH release (Mol Cell Endocrinol 2021)PubMed 33964320